–The PCSK9 synthesis inhibitor from The Medicines Company is getting close to phase 3 trials. More early information continues to accumulate about a novel cholesterol drug under development by The Medicines Company. The drug, which was initially created by Alnylam Pharmaceuticals, uses RNA interference technology to inhibit the synthesis of PCSK9 in the liver. The main…
Novel Drug Could Cut LDL With Just 2 Or 4 Shots A Year
August 30, 2015 by Leave a Comment
A novel drug still in phase 1 studies could dramatically lower cholesterol with only a few injections each year. Because the drug could be given during regular visits to the doctor it might help solve the thorny problem of drug compliance and adherence. Like the recently approved monoclonal antibodies alirocumab and evolocumab, the drug targets PCSK9 to lower LDL,…
Recent Comments